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AbstrACt
Objective To assess the effect of cannabis legalisation 
on health effects and healthcare utilisation in Colorado 
(CO), the first state to legalise recreational cannabis, when 
compared with two control states, New York (NY) and 
Oklahoma (OK).
Design We used the 2010 to 2014 Healthcare Cost and 
Utilisation Project (HCUP) inpatient databases to compare 
changes in rates of healthcare utilisation and diagnoses in 
CO versus NY and OK.
setting Population-based, inpatient.
Participants HCUP state-wide data comprising over 
28 million individuals and over 16 million hospitalisations 
across three states.
Main outcome measures We used International 
Classification of Diseases-Ninth Edition codes to assess 
changes in healthcare utilisation specific to various 
medical diagnoses potentially treated by or exacerbated 
by cannabis. Diagnoses were classified based on weight 
of evidence from the National Academy of Science (NAS). 
Negative binomial models were used to compare rates of 
admissions between states.
results In CO compared with NY and OK, respectively, 
cannabis abuse hospitalisations increased (risk ratio (RR) 
1.27, 95% CI 1.26 to 1.28 and RR 1.16, 95% CI 1.15 to 
1.17; both p<0.0005) post-legalisation. In CO, there was a 
reduction in total admissions but only when compared with 
OK (RR 0.97, 95% CI 0.96 to 0.98, p<0.0005). Length of stay 
and costs did not change significantly in CO compared with 
NY or OK. Post-legalisation changes most consistent with 
NAS included an increase in motor vehicle accidents, alcohol 
abuse, overdose injury and a reduction in chronic pain 
admissions (all p<0.05 compared with each control state).
Conclusions Recreational cannabis legalisation is 
associated with neutral effects on healthcare utilisation. In 
line with previous evidence, cannabis liberalisation is linked 
to an increase in motor vehicle accidents, alcohol abuse, 
overdose injuries and a decrease in chronic pain admissions. 
Such population-level effects may help guide future 
decisions regarding cannabis use, prescription and policy.
IntrODuCtIOn
Over 147 million people, or 2.5 per cent 
of the world’s population, use cannabis 
(marijuana),1 and more than 20 million 
Americans have reported the use of cannabis 
in the past 30 days.1 Because cannabis use is 
a federal crime, clinical studies have been 
challenging to pursue resulting in substan-
tial knowledge gaps regarding actual health 
consequences. Thirty-three states and the 
District of Columbia now allow cannabis for 
the treatment of medical conditions.2 Of 
these, nine have recently legalised cannabis 
for recreational use. Given such pervasive 
policy changes, understanding potential 
shifts in healthcare utilisation is vital.
Recently, an extensive and rigorous 
summary of the current evidence on health 
effects of cannabis was developed by a 
committee of experts appointed by the US 
National Academy of Science (NAS) focusing 
on systematic reviews and high-quality 
primary research.3 The health endpoints 
assessed in the NAS summary included 
oncological, cardiometabolical, respiratory, 
strengths and limitations of this study
 ► The study focuses on the impact of recreational can-
nabis legalisation on hospital admissions instead of 
its legal or societal effects.
 ► This study utilises state-wide hospital admission 
data comprising over 28 million individuals and over 
16 million hospitalisations. 
 ► Effects on hospital admissions are evaluated in 
Colorado, the first state to legalise recreational can-
nabis, but compared with only two control states, 
New York and Oklahoma.
 ► Follow-up data after recreational cannabis legalisa-
tion only includes two subsequent years.
 ► Physician coding with International Classification 
of Diseases-Ninth Edition  codes does not capture 
potentially important mediators related to cannabis 
use.
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immunological and psychiatric disorders as well as 
outcomes related to injury and death (ie, motor vehicle 
accidents). While the NAS summary represents a valuable 
starting place that makes use of the available data, we 
do not yet know whether that evidence, based largely on 
small studies, will translate into real-world ramifications 
after legalisation of recreational cannabis.
On 10 December, 2012, Colorado enacted Colorado 
Amendment 64, legalising recreational cannabis. Following 
this date, adults aged 21 or older could grow cannabis 
plants privately, legally possess all cannabis from these 
plants and give cannabis as a gift to other adults aged 21 
or older.4 After 1 January, 2014, recreational cannabis 
could be legally purchased in retail stores.5 We hypothe-
sised that changes in healthcare utilisation and diagnoses 
most consistent with NAS-based evidence occur when 
access to recreational cannabis becomes liberalised.
MethODs
We used the Agency for Healthcare Research and Quality 
(AHRQ)-funded Healthcare Cost and Utilisation Project 
(HCUP) database to measure inpatient healthcare utilisa-
tion and diagnoses in Colorado (CO) between 2010 and 
2014. HCUP is a state-wide database containing all listed 
inpatient diagnoses and procedures, discharge status, 
patient demographics and charges for all patients, regard-
less of payer (eg, Medicare, Medicaid, private insurance, 
uninsured).
Comparisons were made with two control states in 
order to address possible secular trends. New York (NY), 
the most populous state with inpatient HCUP data avail-
able up to 2014 was selected, and, to counter this coastal 
and largely urban state, we also selected Oklahoma (OK), 
a predominately rural state directly adjacent to CO with 
HCUP hospitalisation data up to 2014. We used separate 
HCUP databases for CO, NY and OK. Unlike the National 
Inpatient Sample (NIS), which is (by definition) a sample, 
these state-specific databases include data from every 
actual admission, providing direct and complete infor-
mation regarding all healthcare utilisation. Both primary 
and secondary diagnoses were extracted from each HCUP 
database for each admission used: up to 30 International 
Classification of Diseases-Ninth Edition (ICD-9) codes 
in CO, 25 in NY and 16 in OK were provided for each 
encounter. Annual demographical data, including age, 
sex and race, was obtained from the US Census Bureau. 
Only month and year were available in all HCUP data-
bases; as legalisation took effect on 10 December, 2012, 
hospitalisations following December 2012 were consid-
ered ‘after’ enactment of the law. Patients with missing 
information on age, sex, race and year of encounter were 
excluded.
Age, sex, race, income level and insurance payer were 
recorded at each healthcare encounter. Hispanic ethnicity 
was not coded in the OK State Department of Health 
data source. In order to use comparable categorisations 
across the three states, we separated race into white, 
black, Native American and other. In addition to the 
population-level variables age, sex and race, we obtained 
the following covariates at the individual level for each 
age, sex and race population strata: (1) income level, (2) 
proportion of HCUP individuals living in an urban versus 
rural setting, (3) with a diagnosis of tobacco use, (4) 
alcohol abuse and (5) psychiatric disorders. The latter 
three covariates were available from ICD-9 codes. Income 
level was categorised by quartiles using the median house-
hold income for each patient’s postal code. Income level 
was not available for OK.
We first performed a validation analysis to assess 
changes in cannabis abuse diagnoses in CO after versus 
before recreational cannabis legalisation and compared 
those rates to changes in NY and OK over the same time 
period. To determine changes in overall healthcare util-
isation, we assessed changes in total number of hospital-
isations, length of inpatient stay and healthcare costs. We 
estimated the cost of each hospitalisation by multiplying 
the charges by a cost-to-charge ratio for the admitting 
hospital for the given year. For NY and CO, we used the 
all-payer cost-to-charge ratios provided by HCUP. When 
the all-payer cost-to-charge ratio was missing, we applied 
the average cost-to-charge ratio particular to state and 
year. As HCUP does not provide cost-to-charge ratios 
for OK, we assumed a constant state-wide cost-to-charge 
ratio (0.3119 as derived from the Institute for Health 
and Socio-Economic Policy calculations of federal cost 
reports) to estimate healthcare costs in OK6; we then 
conducted a sensitivity analysis setting the cost-to-charge 
ratio for OK to equal to the average for NY and CO for the 
corresponding year. See online supplementary eMethods 
and eTable 1 for additional details.
We used ICD-9 codes (eTable 2) to assess changes in 
healthcare utilisation specific to various medical diag-
noses potentially treated by or exacerbated by cannabis 
use as identified by the NAS summary. For each health 
endpoint of interest in the NAS review, the weight of 
evidence regarding the statistical association of recre-
ational cannabis with a specific health endpoint or the 
therapeutic use of cannabis had previously been catego-
rised into substantial, moderate, limited or no evidence.3 
We opted to focus on NAS health endpoints with either 
substantial or moderate evidence.
Because diagnoses of alcohol or other substance 
abuse ‘in remission’ may have been incidental and 
not directly responsible for the hospitalisation, we 
performed a sensitivity analysis where we removed ‘in 
remission’ diagnoses from the group of ICD-9 codes 
defining alcohol abuse and other substance abuse 
(eTable 2).
Finally, to take into account the additional effect of 
recreational cannabis related to availability in retail 
stores we performed sensitivity analyses for all health-
care utilisation (total number of admissions, length of 
stay, costs) and NAS-evidence based outcomes investiga-
tions utilising 1 January, 2014, as the change of policy 
date.
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Certification to use de-identified HCUP data was 
obtained from the University of California, San Francisco 
Committee on Human Research.
statistical analysis
Demographical and lifestyle characteristics are presented 
as mean ±SD or n (% of total admissions) and were 
compared between states using linear, logistical and 
multinomial models as appropriate. Rates of admis-
sions for NAS diagnoses (with the population size as the 
denominator) were compared between states using nega-
tive binomial models.
To assess the effects of recreational cannabis legalisa-
tion, we used negative binomial models for the number 
of admissions, both overall and for particular diagnoses, 
with the log of the subgroup population sizes as an offset 
and the use of robust standard errors. Analogous linear 
models were used for length of stay and cost, which were 
both log-transformed in order to meet normality assump-
tions. All models were adjusted for age, race, sex, income 
level, urbanicity, diagnosis of alcohol abuse, tobacco use 
and psychiatric disorders. Adjustment for diagnosis of 
psychiatric disorders was not performed in the presence 
of a psychiatric outcome. In order to relax the linearity 
assumption, each 5 year age range was included as a sepa-
rate category. To flexibly model secular patterns, year was 
included as a categorical rather than continuous variable 
(with a category for each year between 2010 and 2014). 
The crucial predictors in our model included an indi-
cator for CO (versus the comparison state) and interac-
tions of this indicator with two continuous linear spline 
basis functions, year-2012, and max (0, year-2012). The 
main effect for CO estimated the between-state risk ratio 
(RR) in 2012, the first interaction estimated the slope of 
the between-state RR in 2010 to 2012, and the second esti-
mated the change in slope after 2012. The first interac-
tion was used to project the counterfactual 2013 to 2014 
rates in CO that would be expected in the absence of 
legalisation, while the second was used to capture the 
legalisation effect. Like a standard interrupted time series 
(ITS) model, our model assumed that the between-state 
RR changed linearly at different rates before and after the 
intervention, but used the categorical indicator for year 
to relax the standard ITS assumption of piecewise linear 
trends in the underlying state-specific rates, substantially 
improving model fit. The same model was used in the 
sensitivity analysis using 1 January, 2014, (date of legal 
retail cannabis sales) as change of policy date.
A two-tailed p<0.05 was considered statistically signifi-
cant for the validation analysis (cannabis use) and anal-
yses related to overall healthcare utilisation. In order to 
minimise false positive results and to account for secular 
trends that might differ across different populations, we 
assessed for validation in comparisons versus NY and then 
OK separately.
In order to address possible false positives due to 
multiple hypotheses testing in assessing the diagnoses 
with moderate or substantial evidence described in the 
NAS document, we employed stringent standards: to be 
considered ‘positive,’ the comparisons between CO and 
each of the other two states needed to be in the direction 
expected from the NAS report, each exhibiting statistical 
significance using a two-tailed alpha of 0.05. A ‘positive’ 
designation also required absence of a statistically signif-
icant difference between NY versus OK using a two-tailed 
alpha of 0.05. All analyses were performed using Stata 
V.15 (StataCorp, College Station, Texas).
Patient and public involvement
The patients and public were not involved in the study.
results
baseline characteristics
The total number of admissions between 2010 and 2014 
are shown for each state in table 1. Patients in CO were 
generally younger, more commonly female, and less 
ethnically diverse. Wealth in CO was less equally distrib-
uted, with a higher proportion of individuals with lower 
income in CO compared with NY. Finally, admission rates 
were lower in CO than the control states for most NAS 
diagnoses, with exceptions for pre-diabetes and post-trau-
matic stress disorder.
study validation
Over 2010 to 2014, the change in rates of cannabis abuse 
admissions after versus before recreational cannabis 
legalisation in 2012 was greater in CO than in NY and OK 
(RR 1.27, 95% CI 1.26 to 1.28 and RR 1.16, 95% CI 1.15 
to 1.17; both p<0.0005, respectively) (figure 1A,B). No 
significant changes comparing the two control states, NY 
and OK, were observed over the same time period (RR 
0.93, 95% CI 0.87 to 1.00, p=0.05).
Inpatient healthcare utilisation after cannabis legalisation
Number of admissions
In unadjusted analyses, CO, NY and OK had a similar 
number of total admissions before versus after recreational 
cannabis legalisation (figure 2A). After adjusting for 
covariates, there was a reduction of number of admissions 
following cannabis legalisation in CO when compared 
with OK (RR 0.97, 95% CI 0.96 to 0.98, p<0.0005). The 
point estimate was similar when comparing CO to NY, 
but did not reach statistical significance (RR 0.99, 95% CI 
0.98 to 1.01, p=0.47). Results were similar in sensitivity 
analysis using 1 January, 2014, as change of policy date 
(CO vs OK: RR 0.96, 95% CI 0.96 to 0.96, p<0.0005 and 
CO vs NY: RR 0.99, 95% CI 0.96 to 1.02, p=0.59).
Length of stay
The median length of stay also remained similar after 
cannabis legalisation across the three states in unad-
justed analyses (figure 2B). After adjusting for covariates, 
length of inpatient stay did not change significantly in CO 
following the law change when compared with each of 
the two control states (1.75% annual reduction, 95% CI 
−12.25% to 10.01% in CO vs NY, and 3.46% annual 
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Table 1 Clinical characteristics of the three study states over the 2010 to 2014 period
Colorado New York Oklahoma P value
Total population 5 197 237 19 594 599 3 819 383
Total admissions 2 088 909 11 726 283 2 334 988
Total admissions/1,000 population 402±0.27 598±0.17 611±0.40 0.0001
Demographics
  Age – yr 45±28 49±28 48±28 0.0001
  Male – no. (%) 870 573 (42) 5 087 181 (41) 954 848 (43) 0.0001
  Race – no. (%) 0.0001
  White 1 548 099 (74) 6 406 582 (55) 1 879 727 (81)
  Black 102 444 (5) 2 083 366 (18) 202 420 (9)
  Native American 13 143 (1) 36 216 (0.3) 131 714 (6)
  Other 425 223 (20) 3 200 119 (27) 121 127 (5)
Lifestyle
  Median household income, US$ (quartiles for patient 
postal code) – no. (%)
0.0001
  Quartile 1 617 537 (30) 3 087 192 (28) No data
  Quartile 2 558 760 (27) 2 623 087 (24)
  Quartile 3 470 051 (23) 2 673 153 (24)
  Tobacco use – no. (%) 251 566 (12) 1 717 940 (10) 235 685 (14) 0.0001
  Alcohol abuse – no. (%) 112 715 (5) 652 608 (6) 71 931 (3) 0.0001
NAS diagnoses
  Non-seminoma type testicular germ cell cancer – no. 
(%)
405 (0.02) 2487 (0.02) 480 (0.02) 0.0001
  Acute myocardial infarction – no. (%) 39 513 (1.9) 271 285 (2.3) 60 413 (2.6) 0.0001
  Brain haemorrhage – no. (%) 10 963 (0.5) 58 278 (0.5) 10 245 (0.4) 0.0001
  Ischaemic stroke – no. (%) 27 986 (1.3) 194 478 (1.7) 45 602 (2) 0.0001
  Metabolic syndrome & diabetes – no. (%) 294 821 (14) 2 301 835 (20) 465 353 (20) 0.0001
  Pre-diabetes – no. (%) 42 544 (2) 73 407 (0.6) 24 246 (1) 0.0001
  Bronchitis – no. (%) 65 265 (3) 429 230 (4) 131 343 (6) 0.0001
  Motor vehicle accidents – no. (%) 14 941 (0.7) 59 686 (0.5) 13 692 (0.6) 0.0001
  Overdose injury – no. (%) 10 933 (0.5) 40 226 (0.3) 12 147 (0.5) 0.0001
  Substance use disorder – no. (%) 158 244 (7.6) 974 856 (8.3) 109 305 (4.7) 0.0001
  Anxiety disorders – no. (%) 131 426 (6.4) 595 478 (5.2) 139 627 (6.1) 0.0001
  Anxiety disorders (except social anxiety) – no. (%) 51 913 (2.5) 283 280 (2.4) 65 279 (2.8) 0.0016
  Bipolar disorders – no. (%) 52 348 (2.5) 287 735 (2.5) 61 411 (2.6) 0.0001
  Depressive disorders – no. (%) 213 851 (10) 827 932 (7) 190 083 (8) 0.0001
  Schizophrenia or other psychoses – no. (%) 53 652 (2.6) 352 533 (3) 68 385 (2.9) 0.0001
  Positive symptoms of schizophrenia (ie, hallucinations) 
– no. (%)
2653 (0.1) 9482 (0.1) 3531 (0.2) 0.0001
  Post-traumatic stress disorder – no. (%) 28 582 (1.4) 75 608 (0.6) 17 101 (0.7) 0.0001
  Social anxiety disorder – no. (%) 295 (0.01) 1090 (0.01) 135 (0.01) 0.0295
  Suicide – no. (%) 4957 (0.2) 15 646 (0.1) 4407 (0.2) 0.0001
  Low offspring birth weight – no. (%) 2842 (0.1) 7462 (0.1) 1742 (0.1) 0.0002
  Maternal pregnancy complications – no. (%) 39 343 (1.9) 144 353 (1.2) 40 938 (1.8) 0.0001
  Unemployment/low income – no. (%) 3134 (0.2) 76 789 (0.7) 730 (0.03) 0.0001
  Nausea or vomiting – no. (%) 63 806 (3) 16 211 (1.4) 58 706 (2.5) 0.0001
  Chronic pain – no. (%) 140 209 (6) 234 160 (2) 123 563 (5) 0.0001
Continued
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reduction, 95% CI −16.48% to 37.90% in CO vs OK; 
p=0.30 and p=0.20, respectively). Length of stay did not 
change significantly in CO compared with the control 
states when we used 1 January, 2014, as change of policy 
date.
Healthcare costs
In unadjusted analyses, the three states exhibited similar 
total costs across the study time period (figure 2C and 
eTable 2). In multivariate analyses, healthcare costs 
remained similar in state comparisons (2.99%, 95% CI 
−7.55% to 14.74%, p=0.18 vs NY and 3.45%, 95% CI 
−7.31% to 15.46%, p=0.16 vs OK) after cannabis legalisa-
tion. No meaningful differences of healthcare costs were 
observed in the sensitivity analyses with 1 January, 2014, 
as change of policy date or when we assumed the cost-to-
charge ratio for OK was equal to the average of the other 
states.
Changes in specific diagnoses highlighted by the national 
academy of sciences
Among the diagnoses with either substantial or moderate 
evidence of influence by cannabis per the NAS, we distin-
guished between: (1) a group with no statistically signif-
icant post-legalisation differences between control states 
(NY vs OK p>0.05), suggesting that secular trends unlikely 
explained differences between CO and control states 
(figure 3) and (2) a group with significant differences in 
diagnoses post-legalisation between control states (NY vs 
OK p<0.05) (eFigure 1).
In the NY versus OK p>0.05 group (figure 3), changes 
in rates of diagnoses after cannabis legalisation reflected 
NAS-based evidence for most health outcomes. Among 
the diagnoses most consistent with NAS-based evidence, 
there was an increase in hospital admissions for motor 
vehicle accidents, alcohol abuse, overdose injury and a 
Colorado New York Oklahoma P value
  Spasticity – no. (%) 5759 (0.3) 12 517 (0.1) 5371 (0.2) 0.0001
  Short-term sleep – no. (%) 652 (0.03) 3364 (0.03) 357 (0.02) 0.0001
  Tourette syndrome – no. (%) 428 (0.02) 2784 (0.02) 336 (0.01) 0.0001
  Increased appetite & weight gain – no. (%) 1022 (0.05) 3017 (0.03) 651 (0.03) 0.0001
Admission diagnoses listed were based on those found influenced by cannabis in the 2017 NAS review.3 Substance use disorder includes 
dependence or abuse of alcohol, tobacco or other illicit drug. All variables pertain to the 2010 to 2014 period. Plus-minus values are 
means±SD. No. (%) indicates number of admissions with a specific demographical/lifestyle characteristic or NAS diagnosis (% of total 
admissions). A P value less than 0.05 is considered statistically significant. NAS, National Academy of Science; yr, years. 
Table 1 Continued 
Figure 1 Multivariate adjusted rates of admissions for cannabis abuse over 2010 to 2014 in Colorado, site of implementation 
of the 2012 recreational cannabis legalisation policy, compared with New York (A) and Oklahoma (B), control states without 
cannabis legalisation. Red lines show the predicted rates of admissions for cannabis abuse had the cannabis legalisation policy 
not been instituted. The comparison between Colorado and the control states with regards to change of RR slope within the 
2010 to 2012 period (pre-legalisation) and 2012 to 2014 period (post-legalisation), as well of the overall RR slope change, are 
also represented for the Colorado versus New York (A) and Colorado versus Oklahoma (B) comparisons. Red lines show the 
predicted rates of admissions for cannabis abuse had the cannabis legalisation policy not been instituted. Each model was 
adjusted for age, gender and race and state-level characteristics (see methods section for further details). RR, risk ratio; vs, 
versus. 
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decrease of chronic pain hospitalisations after recre-
ational cannabis legalisation (each meeting statistical 
significance for both comparisons with control states). 
When using less stringent criteria (p<0.05 for both 
comparisons with NY and OK, but where the relative risk 
for only one comparison was in the same direction as 
NAS), admissions for abuse of other substances and social 
anxiety disorder also increased with recreational cannabis 
legalisation (figure 3). Effects of cannabis liberalisation 
on psychiatric outcomes (schizophrenia and bipolar 
disorders) were either not consistent or weakly consis-
tent with NAS (figure 3). When differences between the 
two control states (NY and OK) were also significantly 
different (suggesting effects potentially related to secular 
trends)(eFigure 1), changes in diagnoses were mostly not 
concordant with NAS findings or one of the comparisons 
between CO and either NY or OK did not exhibit statis-
tical significance. Changes of the risk over time with coun-
terfactuals are shown for each NAS diagnosis in online 
supplementary eFigures 2-15.
In the sensitivity analysis using 1 January, 2014, as 
change of policy date (eTable 3), the main findings high-
lighted in the primary analysis using our stringent criteria 
(increase of admissions for alcohol abuse, motor vehicle 
accidents, overdose injury and decrease of chronic pain 
hospitalisations) again met the same criteria in favour of 
significant associations, except for overdose injury and 
chronic pain admissions (the latter meeting two of the 
three criteria described in the Methods). In sensitivity 
analyses removing ‘in remission’ diagnoses, no mean-
ingful changes were observed (relevant to alcohol abuse 
and abuse of other substances).
DIsCussIOn
Principal findings
Legalisation of recreational cannabis was associated with 
more cannabis abuse and minimal effects on overall 
healthcare utilisation. Changes in specific medical diag-
noses post-legalisation reflected previously published 
substantial or moderate evidence on the health effects 
of cannabis, including an increase in motor vehicle acci-
dents, alcohol abuse, overdose injury and a decrease of 
chronic pain admissions.
The increased frequency of hospitalisations for 
cannabis abuse in CO helps to validate the concept that 
legalisation would result in greater use.
Effects of recreational cannabis legalisation on health-
care utilisation appeared to be overall neutral. There was 
no evidence that either the length of stay or healthcare 
costs changed following liberalisation of recreational 
cannabis. There was a reduction of overall hospitalisa-
tions in CO when compared with OK, but not compared 
with NY, potentially because unaccounted state-level 
characteristics may have driven overall admissions differ-
ently. Moreover, in the US healthcare system, hospitalised 
individuals tend to be sicker, with more severe forms of 
specific illnesses and higher inpatient costs compared 
with outpatients. Therefore, our conclusions on overall 
neutral effects of recreational cannabis on healthcare 
costs only reflect higher inpatient costs and not overall 
costs. Outpatient costs may include use of specific medi-
cations or substance detoxification programmes that are 
not captured in our study and may be more cost-effective 
compared with inpatient treatments.
Following legalisation of recreational cannabis, changes 
in rates of medical diagnoses reflected NAS-based 
evidence for most health outcomes. The absence of statis-
tically significant differences in these outcomes between 
the two control states (NY and OK) over the same time 
period provides some evidence that these observed differ-
ences were less likely related to broader secular trends. 
After legalisation of recreational cannabis, there was an 
increase in motor vehicle accidents, alcohol abuse, over-
dose injury and a decrease of chronic pain admissions. In 
addition to information provided in the NAS summary,3 
the association of cannabis with motor vehicle accidents 
has been highlighted by recent literature.7 8 Consistent 
Figure 2 Healthcare utilisation over 2010 to 2014 in 
Colorado, site of implementation of the 2012 recreational 
cannabis legalisation policy, and in New York and Oklahoma, 
control states without cannabis legalisation. The total number 
of admissions/1000 population per year, the median length of 
stay per year and the median costs per individual per year are 
shown in panels A, B and C, respectively, for the three states. 
Error bars denote IQRs. LOS=length of stay.
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with our findings, a substantial bidirectional comorbidity 
between cannabis use and alcohol use has been previ-
ously demonstrated, resulting in a moderate level of 
evidence designation for this relationship per the NAS.9 
Also compatible with the NAS summary, we report that 
recreational cannabis legalisation was associated with an 
increasing number of admissions for overdose injury. 
These included overdose of analgesics, barbiturates, seda-
tive, hypnotics and psychotropic drugs (eTable 2). This 
finding underlines the association of cannabis use with 
other behaviours of drug addiction as highlighted by a 
recent cross-sectional survey of over 30 000 communi-
ty-living US adults.10 Finally, reduction of chronic pain, 
especially neuropathic pain, in cannabis users is well 
known, although prior literature has focused on medical 
rather than recreational cannabis.11 12
Except for social anxiety, the effects of recreational 
cannabis legalisation on admissions for psychiatric disor-
ders (schizophrenia, bipolar disorder, depression) were 
weakly or not consistent with prior NAS-evidence. This 
finding may be related to residual confounding by state-
level characteristics, unaccounted secular trends or insuf-
ficient longitudinal follow-up.
We demonstrate that admissions for abuse of alcohol 
or other substances remains higher after recreational 
cannabis legalisation in a sensitivity analysis without ‘in 
remission’ diagnoses. Overall, these findings suggest that 
when the substance use disorder is in remission, it does 
not play a significant role in overall results.
In our primary analysis, we used 10 December, 2012, as 
the date of recreational cannabis legalisation. Following 
this date, private possession and growth of cannabis 
became legal in Colorado. After 1 January, 2014, recre-
ational cannabis could be legally purchased in retail 
stores.5 To take the additional effect of retail sales of 
recreational cannabis into account, we performed sensi-
tivity analyses using January 2014 as the ‘change of policy’ 
date. We did not observe any meaningful difference in 
the majority of the outcomes studied, suggesting that the 
effect of recreational cannabis on healthcare utilisation 
was independent of availability in stores.
strengths and weaknesses
Although several studies have investigated the health 
effects of cannabis,13 they have relied on small sample 
sizes or have generated conflicting data.14–16 In contrast, 
our findings are derived from HCUP state-wide data 
comprising over 28 million individuals and over 16 million 
hospitalisations across CO, site of the 2012 Amendment 
64, and two controls states without cannabis legalisa-
tion over the same time period. As NY and OK are very 
different geographically and demographically, we believe 
their inclusion as control states represents a strength of 
our manuscript. Specifically, their selection allowed us 
to demonstrate that the effects of recreational cannabis 
legalisation on healthcare utilisation were likely indepen-
dent of living in an urban or rural setting.
Several limitations should be acknowledged. The 
HCUP database relies on physician coding; however, such 
coding for several medical diagnoses listed in table 1 
have been shown to be highly specific with variable 
sensitivity17–20 and HCUP has proven to be a powerful 
Figure 3 Health outcomes with substantial or moderate evidence of a statistical association with cannabis use based on the 
NAS summary statement. Medical diagnoses are identified based on a non-significant (p>0.05) comparison between NY and 
OK (control states without cannabis legalisation) with regards to the change of admission rates for such diagnoses following 
cannabis legalisation. P values for the comparison between CO (site of cannabis legalisation) and NY (rhomboid symbol), or 
between CO and OK (circular symbol) are shown as either <0.05 or >0.05 using a grey scale for evidence of cannabis benefit 
RR <1 shown on the left) and cannabis harm (RR >1 shown on the right); 95% CI are shown for the comparison between CO and 
NY and between CO and OK as solid and dotted lines, respectively. Progressively darker shades of green or red indicate greater 
weight of evidence in the direction of proposed benefit versus harm, respectively, by the NAS. CO, Colorado; NAS, National 
Academy of Science; NY, New York; OK, Oklahoma; RR, risk ratio. 
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tool in large population studies.20–24 Some potentially 
important mediators are not captured by ICD-9 codes, 
such as quantity of cannabis used or formulation (oral 
vs other), although these may be more relevant to iden-
tifying mechanisms and their absence would likely not 
lead to false positive results. Patients may be more likely 
to disclose cannabis use following legalisation of recre-
ational cannabis and clinicians may be more inclined to 
test for it. Hence, we cannot completely exclude detec-
tion bias in the validation analysis showing an increase in 
cannabis abuse admissions following legalisation of recre-
ational cannabis. Moreover, we cannot exclude that the 
increased frequency of cannabis abuse hospitalisations is 
simply related to severity of cannabis abuse rather than to 
a greater prevalence of cannabis use.
As with any observational study, we cannot exclude 
residual confounding as an explanation of our findings. 
However, we adjusted for conventionally recognised 
confounders as appropriate and as available, and, as 
this was largely a study of the same populations pre- 
and post-legalisation, many of the limitations inherent 
to conventional individual-level analyses are likely less 
relevant.
We did not select all US states as controls. Most states 
do not have HCUP data up until the end of 2014, each 
requires a separate HCUP application, and each carries 
significant costs. We acknowledge this represents a limita-
tion as we could not fully account for secular trends that 
might influence results. However, we have adjusted all 
analyses for urbanicity and other state-level differences in 
order to minimise the impact of secular trends. We also 
acknowledge that CO had legalised medical cannabis prior 
to legalisation of recreational cannabis on 10 December, 
2012. However, control states NY and OK had not. We 
could have selected control states that had already medi-
calised cannabis instead of NY and OK, but we acknowl-
edge that complex differences exist among medical 
legalisation regimens among states.25 Hence, we believe 
selection of control states with diverse medical legalisa-
tion regimens would have primarily reduced our power to 
detect a real difference rather than contribute to any false 
positive spurious results. In our study, we demonstrate 
that legalisation of recreational cannabis is associated 
with more admissions for cannabis abuse or cannabis use 
disorder. Prior large, multi-state, population-based anal-
yses have shown that legalisation of medical cannabis is 
associated with increased cannabis use, but not increased 
cannabis use disorder.26 One could speculate that medical 
cannabis consumption is more controlled and rationed 
when compared with recreational cannabis, the latter 
available in both retail stores and private homes and 
therefore perhaps more easily abused. Further studies 
are needed to quantify the amount of cannabis consump-
tion (in grams) in states where only medical cannabis is 
legal versus states where both medical and recreational 
cannabis are allowed.
The HCUP database does not capture information 
regarding outpatient activity and therefore these findings 
are restricted to hospital-based medicine. However, even 
inclusion of outpatient data would not capture individ-
uals with a specific condition or diagnosis who are not 
in formal treatment. Indeed, treatment databases do not 
capture all individuals in the population. This gap may be 
especially large for substance use disorders. Many individ-
uals with substance use disorders may never enter treat-
ment; even those who do more likely receive outpatient 
treatment, rather than a hospitalisation, so they may not 
have been included in our study.
Our use of stringent criteria in assessing changes 
related to NAS diagnoses may have been too conservative, 
leading to a sacrifice of false negatives in order to avoid 
false positives.
Finally, our study was limited to 2 year follow-up after 
recreational cannabis legalisation, and we therefore 
cannot comment on long-term effects that may result.
COnClusIOns
In conclusion, recreational cannabis legalisation is associ-
ated with an expected increase in cannabis use disorder. 
Overall effects on inpatient healthcare utilisation appear 
to be neutral, with subtle changes in various components 
of that utilisation likely occurring due to changes in 
the types of admissions observed. Measurable effects of 
recreational cannabis legalisation on increasing hospital-
isations for motor vehicle accidents, alcohol abuse, over-
dose injury and reducing chronic pain admissions are 
consistent with previously published evidence. These data 
provide the first description of population-level effects 
that may help guide future decisions regarding cannabis 
policy, individuals considering using cannabis and physi-
cians caring for those who may choose to consume it.
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